• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Repligen Corporation

    3/3/25 4:45:40 PM ET
    $RGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RGEN alert in real time by email
    NT 10-K 1 d812625dnt10k.htm NT 10-K NT 10-K
    OMB APPROVAL
    OMB Number:   3235-0058
    Expires:   April 30, 2025
    Estimated average burden
    hours per response   2.50

    SEC FILE NUMBER

    000-14656

    CUSIP NUMBER

    759916109

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 12b-25

     

     

    NOTIFICATION OF LATE FILING

     

    (Check one):   

    ☒ Form 10-K  ☐ Form 20-F  ☐ Form 11-K

    ☐ Form 10-Q  ☐ Form 10-D  ☐ Form N-CEN  ☐ Form N-CSR

      For Period Ended: December 31, 2024
      ☐ Transition Report on Form 10-K
      ☐ Transition Report on Form 20-F
      ☐ Transition Report on Form 11-K
      ☐ Transition Report on Form 10-Q
      For the Transition Period Ended:               

     

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

    PART I — REGISTRANT INFORMATION

    Repligen Corporation

    Full Name of Registrant

    Not applicable

    Former Name if Applicable

    41 Seyon Street

    Address of Principal Executive Office (Street and Number)

    Waltham, Massachusetts 02453

    City, State and Zip Code

     

    SEC 1344 (01-19)    Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

     

     

    PART II — RULES 12b-25(b) AND (c)

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    ☒     (a)   The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
      (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

    PART III — NARRATIVE

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

    Repligen Corporation (the “Company”) has determined that it will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) within the prescribed time period for such filing without unreasonable effort or expense. The Company has dedicated significant resources to completing the 2024 Form 10-K and is working to complete the necessary procedures to file the 2024 Form 10-K as soon as practicable. The Company requires additional time to complete the procedures relating to its year-end reporting process, including the completion of the audit of the Company’s financial statements by the Company’s independent auditors for inclusion in the 2024 Form 10-K. The Company expects to file the 2024 Form 10-K within the extension period provided under Rule 12b-25 under the Securities Exchange Act of 1934, as amended.

    The Company does not expect the financial results in the 2024 Form 10-K to differ from the financial results for the quarter and full year ended December 31, 2024 set forth in the Company’s press release dated February 20, 2025, which is filed as an exhibit to the Company’s Form 8-K furnished with the Commission on February 20, 2025 (the “2024 Earnings Release”).

     

     

    PART IV — OTHER INFORMATION

     

    (1)       Name and telephone number of person to contact in regard to this notification
        Jason K. Garland          (781)          250-0111
        (Name)     (Area Code)     (Telephone Number)
    (2)     Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  ☒ Yes ☐ No
    (3)     Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  ☒ Yes ☐ No
        If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
        The Company’s financial results for the quarter and full year ended December 31, 2024, compared to the financial results for the corresponding periods in the prior fiscal year are set forth in the 2024 Earnings Release.

     

     

     


    Forward-Looking Statements

    This Notification of Late Filing contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, statements regarding the expected timing of the filing of the 2024 Form 10-K and that the financial results included in the 2024 Form 10-K are not expected to be different from those disclosed in the 2024 Earnings Release, are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, that the Company has underestimated the efforts and timing for filing the 2024 Form 10-K, risks and uncertainties around the effectiveness of the Company’s disclosure controls and procedures and the effectiveness of the Company’s internal control over financial reporting, the risk that the financial results reported in the 2024 Form 10-K will differ from those reported in the 2024 Earnings Release, as well as those risks and uncertainties identified in the Company’s filings with the U.S. Securities and Exchange Commission (the “Commission”), including the Company’s Form 10-K for the year ended December 31, 2024 and in any subsequent filings with the Commission, including its Current Reports on Form 8-K, its Quarterly Reports on Form 10-Q and its upcoming 2024 Form 10-K, which are available at the Commission’s website at www.sec.gov. Any such risks and uncertainties could materially and adversely affect the Company’s results of operations, its profitability and its cash flows, which would, in turn, have a significant and adverse impact on the Company’s stock price. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.


    Repligen Corporation

    (Name of Registrant as Specified in Charter)

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: March 3, 2025     By:  

    /s/ Jason K. Garland

          Jason K. Garland
          Chief Financial Officer
    Get the next $RGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RGEN

    DatePrice TargetRatingAnalyst
    4/29/2025$160.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$155.00In-line
    Evercore ISI
    2/10/2025$200.00Buy
    TD Cowen
    12/17/2024$165.00Hold
    Canaccord Genuity
    11/14/2024Peer Perform
    Wolfe Research
    8/28/2024$180.00Overweight
    Wells Fargo
    6/26/2024$180.00 → $155.00Hold → Buy
    Deutsche Bank
    6/18/2024Neutral
    Guggenheim
    More analyst ratings

    $RGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Repligen Corporation to Present at Upcoming May Investor Conferences

      WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the following May investor conferences. RBC Capital Markets' 2025 Global Healthcare Conference, being held in New York on May 20-21. Jason K. Garland, Chief Financial Officer, is scheduled to participate in an analyst-led discussion on May 20 at 3:35 p.m. ET, in addition to a series of one-on-one meetings with investors.Craig-Hallum's 22nd Annual Institutional Investor Conference, being held in Minneapolis on May 28. Jason K. Garland, Chief Financial Officer will participate in a series

      5/7/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Reports First Quarter 2025 Financial Results

      Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer

      4/29/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen to Report First Quarter 2025 Financial Results

      WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company

      4/15/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      3/18/25 3:58:05 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Madaus Martin D bought $201,776 worth of shares (1,615 units at $124.94) (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      6/14/24 6:07:59 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Barthelemy Nicolas bought $150,540 worth of shares (1,200 units at $125.45), increasing direct ownership by 35% to 4,668 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      6/14/24 5:42:58 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Financials

    Live finance-specific insights

    See more
    • Repligen Reports First Quarter 2025 Financial Results

      Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025. Olivier Loeillot, President and Chief Executive Officer

      4/29/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen to Report First Quarter 2025 Financial Results

      WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company

      4/15/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

      WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph

      3/4/25 7:30:00 AM ET
      $MASS
      $RGEN
      Industrial Machinery/Components
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Repligen Corporation

      SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

      11/14/24 1:22:37 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Repligen Corporation

      SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

      9/10/24 5:08:30 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

      SC 13G/A - REPLIGEN CORP (0000730272) (Subject)

      2/14/24 10:02:59 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Repligen upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Repligen from Peer Perform to Outperform and set a new price target of $160.00

      4/29/25 2:20:14 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Evercore ISI initiated coverage on Repligen with a new price target

      Evercore ISI initiated coverage of Repligen with a rating of In-line and set a new price target of $155.00

      3/18/25 7:55:20 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Repligen with a new price target

      TD Cowen initiated coverage of Repligen with a rating of Buy and set a new price target of $200.00

      2/10/25 7:05:45 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Repligen Corporation

      10-Q - REPLIGEN CORP (0000730272) (Filer)

      4/29/25 4:17:25 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Repligen Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - REPLIGEN CORP (0000730272) (Filer)

      4/29/25 7:32:59 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Repligen Corporation

      DEFA14A - REPLIGEN CORP (0000730272) (Filer)

      4/4/25 4:23:06 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Bylund James covered exercise/tax liability with 454 shares, decreasing direct ownership by 2% to 23,711 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      4/2/25 10:33:47 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Bylund James was granted 381 shares and covered exercise/tax liability with 175 shares, increasing direct ownership by 0.86% to 24,165 units (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      3/20/25 1:51:51 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Hunt Anthony sold $4,080,663 worth of shares (26,756 units at $152.51) and exercised 26,756 shares at a strike of $54.73 (SEC Form 4)

      4 - REPLIGEN CORP (0000730272) (Issuer)

      3/19/25 4:21:04 PM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Repligen Appoints Jacob Johnson As Vice President Investor Relations

      WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garland commented, "Jacob is a terrific addition to the Repligen team, bringing a broad understanding of the bioprocessing tools space, the markets we serve and the growth driver

      4/8/25 7:30:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

      BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is

      12/16/24 8:11:00 AM ET
      $BLFS
      $RGEN
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Repligen Announces CEO Transition Plan

      WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of

      6/13/24 7:00:00 AM ET
      $RGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care